AF
HRMY icon

Amalgamated Financial’s Harmony Biosciences HRMY Stock Holding History

Amalgamated Financial’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$542K Buy
+11,150
New +$455K ﹤0.01% 1478

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's HRMY Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Harmony Biosciences (HRMY) in Q1 2022: 11,150 shares worth $542K. The stake represents ﹤0.01% of the portfolio and ranks #1478 among its holdings.

182 funds tracked by Wall St. Rank hold HRMY as of Q1 2022.

  • Amalgamated Financial held 11,150 shares of Harmony Biosciences worth $542K as of Q1 2022.
  • Harmony Biosciences was a new Amalgamated Financial position in Q1 2022.
  • Harmony Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1478 holding.
  • 182 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.